WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Bohm and Harper lead the streaking Phillies to a sweep of the Nationals with 11Ukraine, Russia exchange drone attacks while Russia continues its push in the eastMateta's hat trick helps Crystal Palace rout Aston Villa 5US troops will complete their withdrawal from Niger by midCompanies are trying to attract more smartphone users across Africa. But there are risksWoke DC mayor takes her 14Paul McCartney song starts Paralympics on 100Dive team finds bodies of 2 men dead inside plane in Alaska lakeRecord set for most goals in a single season in the Premier LeagueHyderabad stays in contention for 2nd place in IPL with 4